Podcast appearances and mentions of David Fischer

Podcast Episode Description: “Money Monday with Kevin McCullough: Oil, Gold & Turnaround Stocks” This week on Money Monday, Kevin McCullough dives deep into the market impact of the latest geopolitical developments and economic trends with three top financial experts. • Lou Basenese breaks down how oil markets are reacting to Trump's Houthi offensive and what it means for energy stocks. • David Fischer provides expert insights into the gold market's response to global uncertainty and why investors are turning to precious metals. • Hilary Kramer highlights turnaround stocks that could present major investment opportunities in today's market. If you're looking for actionable insights on the biggest financial moves, this episode is a must-listen! Listen now on Apple Podcasts, Spotify, and SoundCloud!

Dr. Neeraj Agarwal and Dr. Peter Hoskin discuss key abstracts in GU cancers from the 2025 ASCO Genitourinary Cancers Symposium, including novel therapies in prostate, bladder, and kidney cancer and the impact of combination therapies on patient outcomes. TRANSCSRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Oncology Program and professor of medicine at the Huntsman Cancer Institute at the University of Utah, and editor-in-chief of ASCO Daily News. Today, we'll be discussing practice-informing abstracts and other key advances in GU oncology featured at the 2025 ASCO Genitourinary Cancers Symposium. Joining me for this discussion is Dr. Peter Hoskin, the chair of this year's ASCO GU Symposium. Dr. Hoskin is a professor in clinical oncology in the University of Manchester and honorary consultant in clinical oncology at the Christie Hospital, Manchester, and University College Hospital London, in the United Kingdom. Our full disclosures are available in the transcript of this episode. Peter, thank you for joining us today. Dr. Peter Hoskin: Thank you so much, Neeraj. I am very pleased to be here. Dr. Neeraj Agarwal: The GU meeting highlighted remarkable advancements across the spectrum of GU malignancies. What stood out to you as the most exciting developments at the ASCO GU Symposium?  Dr. Peter Hoskin: The theme of this year's meeting was "Driving Innovation, Improving Patient Care," and this reflected ASCO GU's incredible milestone in GU cancer research over the years. We were thrilled to welcome almost 6,000 attendees on this occasion from over 70 countries, and most of them were attending in person and not online, although this was a hybrid meeting. Furthermore, we had more than 1,000 abstract submissions. You can imagine then that it fostered fantastic networking opportunities and facilitated valuable knowledge and idea exchanges among experts, trainees, and mentees. So, to start I'd like to come back to you for a second because the first day started with a focus on prostate cancer and some of the key clinical trials. And congratulations to you, Neeraj, on sharing the data from the TALAPRO-2 trial, which we were eagerly awaiting. I'd love to get your thoughts on the data that you presented. Could you tell us more about that trial, Abstract LBA18?  Dr. Neeraj Agarwal: Yes, Peter, I agree with you. It was such an exciting conference overall and thank you for your leadership of this conference. So, let's talk about the TALAPRO-2 trial. First of all, I would like to remind our audience that the combination of talazoparib plus enzalutamide was approved by the U.S. FDA in June 2023 in patients with metastatic castration-resistant prostate cancer harboring HRR gene alterations, after this combination improved the primary endpoint of radiographic progression-free survival compared to enzalutamide alone in the randomized, double-blind, placebo-controlled, multi-cohort phase 3 TALAPRO-2 trial. In the abstract I presented at ASCO GU 2025, we reported the final overall survival data, which was a key alpha-protected secondary endpoint in cohort 1, which enrolled an all-comer population of patients with mCRPC. So, at a median follow-up of around 53 months, in the intention-to-treat population, the combination of talazoparib plus enzalutamide significantly reduced the risk of death by 20% compared to enzalutamide alone, with a median OS of 45.8 months in the experimental arm versus 37 months in the control arm, which was an active control arm of enzalutamide. This improvement was consistent in patients with HRR alterations with a hazard ratio of 0.54 and in those with non-deficient or unknown HRR status, with a hazard ratio of 0.87. In a post hoc analysis, the hazard ratio for OS was 0.78 favoring the combination in those patients who did not have any HRR gene alteration in their tumors by both tissue and ctDNA testing. Consistent with the primary analysis, the updated rPFS data also favored the experimental arm with a median rPFS of 33.1 compared to 19.5 months in the control arm, and a hazard ratio of 0.667. No new safety signals were identified with extended follow-up. Thus, TALAPRO-2 is the first PARP inhibitor plus ARPI study to show a statistically significant and a clinically meaningful improvement in OS compared to standard-of-care enzalutamide as first-line treatment in patients with mCRPC unselected for HRR gene alterations. Dr. Peter Hoskin: Thank you, Neeraj. That's a great summary of the data presented and very important data indeed. There was another abstract also featured in the same session, Abstract 20, titled “Which patients with metastatic hormone-sensitive prostate cancer benefit more from androgen receptor pathway inhibitors? STOPCAP meta-analyses of individual participant data.” Neeraj, could you tell us more about this abstract? Dr. Neeraj Agarwal: Absolutely, I would be delighted to. So, in this meta-analysis, Dr. David Fischer and colleagues pooled individual participant data from different randomized phase 3 trials in the mHSPC setting to assess the potential ARPI effect modifiers and determine who benefits more from an ARPI plus ADT doublet. The primary outcome was OS for main effects and PFS for subgroup analyses. Prostate cancer specific survival was a sensitivity outcome. The investigators pooled data from 11 ARPI trials and more than 11,000 patients. Overall, there was a clear benefit of adding an ARPI on both OS and PFS, with hazard ratios of 0.66 and 0.51, respectively, representing a 13% and 21% absolute improvement at 5 years, respectively, with no clear difference by the class of agent. When stratifying the patients by age group, the effects of adding an ARPI on OS and PFS were slightly smaller in patients older than 75, than in those younger than 65, or aged between 65 and 75 years. Notably, in the trials assessing the use of abiraterone, we saw very little OS effects in the group of patients older than 75, however there was some benefit maintained in prostate-cancer specific survival, suggesting that other causes of death may be having an impact. The effects of the other ARPIs, or ‘lutamides' as I would call them, were similar across all three age subgroups on both OS and PFS. Therefore, the majority of patients with mHSPC benefit from the addition of ARPIs, and the benefits/risks of abiraterone and other ‘amides' must be considered in older patients.  Dr. Peter Hoskin: Thanks, Neeraj. Another great summary relevant to our day-to-day practice. Of course, there's ongoing collection of individual patient data from other key trials, which will allow robust comparison of ARPI doublet with triplet therapy (including docetaxel), guiding more personalized treatment.   Dr. Neeraj Agarwal: I agree with you, Peter, we need more data to help guide personalized treatment for patients with mHSPC and potentially guide de-escalation versus escalation strategies. Now, moving on to a different setting in prostate cancer, would you like to mention Abstract 17 titled, “Overall survival and quality of life with Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901),” presented by Dr. Louise Emmett? Dr. Peter Hoskin: Of course I will. So, ENZA-p was a multicenter, open-label, randomized, phase 2 trial conducted in Australia. It randomized 163 patients into adaptive doses (2 or 4 cycles) of Lu-PSMA-617 plus enzalutamide versus enzalutamide alone as first-line treatment in PSMA-PET-CT-positive, poor-risk, mCRPC. The interim analysis of ENZA-p with median follow-up 20 months showed improved PSA-progression-free survival with the addition of Lu-PSMA-617 to enzalutamide. Here, the investigators reported the secondary outcomes, overall survival, and health-related quality of life (HRQOL). After a median follow up of 34 months, overall survival was longer in the combination arm compared to the enzalutamide arm, with a median OS of 34 months compared to 26 months; with an HR of 0.55. Moreover, the combination improved both deterioration-free survival and health-related quality of life indicators for pain, fatigue, physical function, and overall health and quality of life compared to the control arm. Consistent with the primary analysis, the rPFS also favored the experimental arm with a median rPFS of 17 months compared to 14 months with a HR of 0.61. So, the addition of LuPSMA improved overall survival, and HRQOL in patients with high-risk mCRPC. Dr. Neeraj Agarwal: Thank you, Peter. Great summary, and promising results with Lu-177 and ARPI combination in first line treatment for mCRPC among patients who had two or more high risk features associated with early enzalutamide failure. Before we move on to bladder cancer, would you like to tell us about Abstract 15 titled, “World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration,” presented by Dr. Chad Tang?  Dr. Peter Hoskin: Sure. So, with metastatic-directed therapy (MDT), we have a number of phase 2 studies making up the database, and the X-MET collaboration aimed to consolidate all randomized data on oligometastatic solid tumors. This abstract presented pooled individual patient data from all the published trials involving patients with oligometastatic prostate cancer who received MDT alongside standard of care (SOC) against SOC alone. The analysis included data from five trials, encompassing 472 patients with oligometastatic prostate cancer, and followed for a median of 41 months. Patients were randomly assigned in a 1:1 ratio to receive either MDT plus SOC or SOC alone. The addition of MDT significantly improved PFS. The median PFS was 32 months with MDT compared to 14.9 months with SOC alone, with an HR of 0.45. Subgroup analyses further confirmed the consistent benefits of MDT across different patient groups. Regardless of factors like castration status, receipt of prior primary treatment, stage, or number of metastases, MDT consistently improved PFS. In patients with mHSPC, MDT significantly delayed the time to castration resistance by nine months, extending it to a median of 72 months compared to 63 months in the SOC group with an HR of 0.58. In terms of OS, the addition of MDT improved the 48-month survival rate by 12%, with OS rates of 87% in the MDT+SOC group compared to 75% in the SOC alone group. Dr. Neeraj Agarwal: Thank you, Peter. These data demonstrate that adding MDT to systemic therapy significantly improves PFS, rPFS, and castration resistance-free survival, reinforcing its potential role in the treatment of oligometastatic prostate cancer. So, let's switch gears to bladder cancer and start with Abstract 658 reporting the OS analysis of the CheckMate-274 trial. Would you like to tell us about this abstract?  Dr. Peter Hoskin: Yes, sure, Neeraj. This was presented by Dr. Matt Milowsky, and it was additional efficacy outcomes, including overall survival, from the CheckMate-274 trial which evaluated adjuvant nivolumab versus placebo in patients with high-risk muscle-invasive bladder cancer after radical surgery. The phase 3 trial previously demonstrated a significant improvement in disease-free survival with nivolumab. With a median follow-up of 36.1 months, disease-free survival was longer with nivolumab compared to placebo across all patients with muscle-invasive bladder cancer, reducing the risk of disease recurrence or death by 37%. Among patients who had received prior neoadjuvant cisplatin-based chemotherapy, nivolumab reduced this risk by 42%, whilst in those who had not received chemotherapy, the risk was reduced by 31%. Overall survival also favored nivolumab over placebo, reducing the risk of death by 30% in all patients with muscle-invasive bladder cancer and by 52% in those with tumors expressing PD-L1 at 1% or higher. Among patients who had received prior neoadjuvant chemotherapy, nivolumab reduced the risk of death by 26%, whilst in those who had not received chemotherapy, the risk was reduced by 33%. Alongside this, the safety profile remained consistent with previous findings. Dr. Neeraj Agarwal: Thank you, Peter, for such a nice overview of this abstract. These results reinforce adjuvant nivolumab as a standard of care for high-risk muscle-invasive bladder cancer, offering the potential for a curative outcome for our patients. Dr. Peter Hoskin: I agree with you Neeraj. Perhaps you would like to mention Abstract 659 titled, “Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.” Dr. Neeraj Agarwal: Of course. Dr. Galsky presented additional outcomes from the phase 3 NIAGARA study, which evaluated perioperative durvalumab combined with neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. The study previously demonstrated a significant improvement in event-free survival and overall survival with durvalumab compared to chemotherapy alone, with a manageable safety profile and no negative impact on the ability to undergo radical cystectomy. Among the 1,063 randomized patients, those who received durvalumab had a 33% reduction in the risk of developing distant metastases or death and a 31% reduction in the risk of dying from bladder cancer compared to those who received chemotherapy alone. More patients who received durvalumab achieved a pathological complete response at the time of surgery with 37% compared to 28% in the chemotherapy-alone group. Patients who achieved a pathological complete response had better event-free survival and overall survival compared to those who did not. In both groups, durvalumab provided additional survival benefits, reducing the risk of disease progression or death by 42% and the risk of death by 28% in patients with a pathological complete response, while in those patients without a pathological complete response, the risk of disease progression or death was reduced by 23% and the risk of death by 16% when durvalumab was added to the chemotherapy. Immune-mediated adverse events occurred in 21% of patients in the durvalumab group compared to 3% in the chemotherapy-alone group, with grade 3 or higher events occurring in 3% compared to 0.2%. The most common immune-related adverse events included hypothyroidism in 10% of patients treated with durvalumab compared to 1% in the chemotherapy-alone group, and hyperthyroidism in 3% versus 0.8%. At the time of the data cutoff, these adverse events had resolved in 41% of affected patients in the durvalumab group and 44% in the chemotherapy-alone group. Dr. Peter Hoskin: Thank you, Neeraj, for the great summary. These findings further support the role of perioperative durvalumab as a potential standard of care for patients with muscle-invasive bladder cancer. Dr. Neeraj Agarwal: I concur with your thoughts, Peter. Before wrapping up the bladder cancer section, would you like to mention Abstract 664 reporting updated results from the EV-302 trial, which evaluated enfortumab vedotin in combination with pembrolizumab compared to chemotherapy as first-line treatment for patients with previously untreated locally advanced or metastatic urothelial carcinoma? Dr. Peter Hoskin: Yes, of course. Dr. Tom Powles presented updated findings from the EV-302 study, and in this abstract presented 12 months of additional follow-up for EV-302 (>2 y of median follow-up) and an exploratory analysis of patients with confirmed complete response (cCR). The study had a median follow-up of 29.1 months and previously demonstrated significant improvements in progression-free survival and overall survival with enfortumab vedotin and pembrolizumab. This is now the standard of care in global treatment guidelines. Among the 886 randomized patients, enfortumab vedotin and pembrolizumab reduced the risk of disease progression or death by 52% and the risk of death by 49% compared to chemotherapy. The survival benefit was consistent regardless of cisplatin eligibility or the presence of liver metastases. The confirmed objective response rate was higher with enfortumab vedotin and pembrolizumab at 67.5% compared to 44.2% with chemotherapy. The median duration of response was 23.3 months with enfortumab vedotin and pembrolizumab compared to 7.0 months with chemotherapy. A complete response was achieved in 30.4% of patients in the enfortumab vedotin and pembrolizumab group compared to 14.5% in the chemotherapy group, with the median duration of complete response not yet reached in the enfortumab vedotin and pembrolizumab group compared to 15.2 months in the chemotherapy group. Severe treatment-related adverse events occurred in 57.3% of patients treated with enfortumab vedotin and pembrolizumab compared to 69.5% in the chemotherapy group, while in patients who achieved a complete response, severe adverse events occurred in 61.7% of those treated with enfortumab vedotin and pembrolizumab compared to 71.9% with chemotherapy. Treatment-related deaths were reported in 1.1% of patients treated with enfortumab vedotin and pembrolizumab compared to 0.9% with chemotherapy, with no treatment-related deaths occurring in those who achieved a complete response. These findings clearly confirm the durable efficacy of enfortumab vedotin and pembrolizumab, reinforcing its role as the standard of care for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma, and no new safety concerns have been identified. Dr. Neeraj Agarwal: Thank you for this great summary. Moving on to kidney cancer, let's talk about Abstract 439 titled, “Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate-9ER trial.” Dr. Peter Hoskin: Sure. Dr. Motzer presented the final results from the phase 3 CheckMate-9ER trial, which compared the combination of cabozantinib and nivolumab against sunitinib in previously untreated advanced renal cell carcinoma. The data after more than five years follow-up show that the combination therapy provided sustained superior efficacy compared to sunitinib. In terms of overall survival, we see an 11-month improvement in median OS, 46.5 months for the cabo-nivo versus 35.5 months for sunitinib and a 42% reduction in the risk of disease progression or death, with median progression-free survival nearly doubling – that's 16.4 months in the combination group and 8.3 months with sunitinib. Importantly, the safety profile was consistent with the known safety profiles of the individual medicines, with no new safety concerns identified. Dr. Neeraj Agarwal: Great summary, Peter. These data further support the efficacy of cabo-nivo combination therapy in advanced renal cell carcinoma, which is showing a 11-month difference in overall survival. Dr. Peter Hoskin: Neeraj, before wrapping up this podcast, would you like to tell us about Abstract 618? This is titled “Prospective COTRIMS (Cologne trial of retroperitoneal lymphadenectomy in metastatic seminoma) trial: Final results.” Dr. Neeraj Agarwal: Sure, Peter. I would be delighted to. Dr Heidenrich from the University of Cologne in Germany presented the COTRIMS data evaluating retroperitoneal LN dissection in patients with clinical stage 2A/B seminomas. Seminomas are classified as 2A or B when the disease spreads to the retroperitoneal lymph nodes of up to 2 cm (CS IIA) or of more than 2 cm to up to 5 cm (CS 2B) in maximum diameter, respectively. They account for 10-15% of seminomas and they are usually treated with radiation and chemotherapy. However, radiation and chemo can be associated with long-term toxicities such as cardiovascular toxicities, diabetes, solid cancers, leukemia, particularly for younger patients. From this standpoint, Dr Heidenrich and colleagues evaluated unilateral, modified template, nerve-sparing retroperitoneal lymph node dissection as a less toxic alternative compared to chemo and radiation. They included 34 patients with negative AFP, beta-HCG, and clinical stage 2A/B seminomas. At a median follow-up of 43.2 months, the trial demonstrated great outcomes: a 99.3% treatment-free survival rate and 100% overall survival, with only four relapses. Antegrade ejaculation was preserved in 88% of patients, and severe complications such as grade 3 and 4 were observed in 12% of patients. Pathological analysis revealed metastatic seminoma in 85% of cases, with miR371 being true positive in 23 out of 24 cases and true negative in 100% of cases. It appears to be a valid biomarker for predicting the presence of lymph node metastases. These findings highlight retroperitoneal lymph node dissection is feasible; it has low morbidity, and excellent oncologic outcomes, avoiding overtreatment in 80% of patients and sparing unnecessary chemotherapy or radiotherapy in 10-15% of cases. Dr. Peter Hoskin: Great summary and important data on retroperitoneal lymphadenectomy in metastatic seminoma. These findings will help shape clinical practice. Any final remarks before we conclude today's podcast? Dr. Neeraj Agarwal: Before wrapping up this podcast, I would like to say that we have reviewed several abstracts addressing prostate, bladder, kidney cancers, and seminoma, which are impacting our medical practices now and in the near future. Peter, thank you for sharing your insights with us today. These updates are undoubtedly exciting for the entire GU oncology community, and we greatly appreciate your valuable contribution to the discussion and your leadership of the conference. Many thanks. Dr. Peter Hoskin: Thank you, Neeraj. Thank you for the opportunity to share this information more widely. I'm aware that whilst we have nearly 6,000 delegates, there are many other tens of thousands of colleagues around the world who need to have access to this information. And it was a great privilege to chair this ASCO GU25. So, thank you once again, Neeraj, for this opportunity to share more of this information that we discussed over those few days. Dr. Neeraj Agarwal: Thank you, Peter. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  Find out more about today's speakers:   Dr. Neeraj Agarwal    @neerajaiims    Dr. Peter Hoskin Follow ASCO on social media:      @ASCO on Twitter      ASCO on Bluesky  ASCO on Facebook      ASCO on LinkedIn      Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Peter Hoskin: Research Funding (Institution): Varian Medical Systems, Astellas Pharma, Bayer, Roche, Pfizer, Elekta, Bristol Myers  

En la edición AM, hablamos con Kevin Cowan, académico de la Escuela de Negocios UAI y ex Vicepresidente de la CMF, y con David Fischer, abogado tributario y socio de Binatax. También, con Felipe Posada, Director y Miembro de Comunidad Traders.

En la edición AM, hablamos con Kevin Cowan, académico de la Escuela de Negocios UAI y ex Vicepresidente de la CMF, y con David Fischer, abogado tributario y socio de Binatax. También, con Felipe Posada, Director y Miembro de Comunidad Traders.

Nach der Mitgliederversammlung der SGD gibt es viel zu besprechen: Präsident Holger Scholze ist zurückgetreten, und das Thema „Fanshop-Rückkauf“ hat für hitzige Diskussionen gesorgt. In dieser Folge sprechen Tino und Jens mit David Fischer, Dynamos Geschäftsführer Kommunikation, über die Hintergründe, die Ereignisse und die Auswirkungen auf die Zukunft der Sportgemeinschaft.

Most small business owners excel in their chosen fields, but marketing often feels like uncharted territory. You know you need a website and an email list, but what should your website look like? What should you be sending to your email list? And how do you know if any of it is even working?David Fischer, Founder and CEO of Solutions for Growth and Constant Contact Community Coach, understands these challenges. For 14 years, he and his team have helped small businesses nationwide elevate their marketing efforts and get real results.David joined Dave Charest on the Be a Marketer podcast to share his insights on how to level up your email marketing using the power of segmentation. Simply put, segmentation means dividing your email list into smaller groups based on specific criteria, like demographics, purchase history, or even engagement levels. This allows you to send more personalized and relevant emails that resonate with each subscriber.“The more targeted and more specific the message is to those people, the more it will resonate with them and the better results you're going to get," David explains.Tune in to learn tactical tips for segmenting your email list, understanding the difference between lists and segments, and sending the right message to the right people at the right time.Additional Resources:Email List SegmentationSegment Your ListsEmail List Segmentation Best Practices

On the surface, the election of 1872 might seem insignificant in US history; Ulysses Grant easily won reelection to the White House and his Republican Party maintained their dominance in both houses of Congress. In the south, however, the violence that followed the election at the state and local level was an ominous sign that the era of Reconstruction might soon be over. And, according to Dana Bash and her co-author David Fischer, nowhere saw more violence than Louisiana. In this episode, Dana joins Ben & Bob to discuss her new book America's Deadliest Election: The Cautionary Tale of the Most Violent Election in American History, and how the violence that followed the 1872 election in Louisiana – including the slaughter of 150 unarmed black Americans in the small town of Colfax – laid the foundation for the restoration of white supremacy in the south. Dana Bash is chief political correspondent at CNN, where she also anchors Inside Politics and co-anchors State of the Union alongside Jake Tapper. This episode was edited by Gary Fletcher.

On episode #181, I spoke with David Fischer about the new movie, Sight. Here are some key questions and topics from our discussion:Who is Ming Wang?What made David want to produce a movie based on his lifeThe importance of Ming Wang's storyAnd much more... Tune in for a great conversation!Links:David on LinkedInCheck out the movie hereOur Sponsors:This is a Good Catholic Podcast.  If you're interested in purchasing a Good Catholic digital series, use code GBS for 20% off your total order.Looking for the perfect Catholic gift? Check out The Catholic Company and find it today! Use code SAINTS20OFF for 20% off your next purchase! Support the Show.

Dr. David E. Fischer graduated from Stanford University with a BA degree in philosophy and went on to graduate studies at Fuller Theological Seminary and Princeton Seminary. Dr. Fischer founded Living Word Bible College in Southern California in 1971. He wrote curricula for 15 courses, including many chapter by chapter Bible book studies, and was a teacher for students from around the world for over 35 years. This interview we will here David's thoughts and insights on Nehemiah.

Money Monday: March 25, 2024. CRITICAL FINANCIAL NEWS! Steve has an important conversation with David Fischer from Landmarkgold about critical financial issues that are happening now and very soon. Will the stock market crash again? Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

Tonight, the AHH Crew is returning to the world of David Fischer as they break down his 2007 masterpiece, Zodiac!The film tells the story of the manhunt for the Zodiac Killer, a serial murderer who terrorized the San Francisco Bay Area during the late 1960s and early 1970s, taunting police with letters, bloodstained clothing, and ciphers mailed to newspapers. The case remains one of the United States' most infamous unsolved crimes.But first: HOMETOWN HAUNTS & HOPS HORROR CON is returning to Mayflower Brewing on 9/21, Mike, Andrew & Matt will be hosting HALFWAY TO HALLOWEEN horror movie trivia in May, SALEM'S LOT is headed directly to Max, updates on THE EXORCIST & HALLOWEEN franchises, and a new ISLAND OF DR. MOREAU movie with... Anthony Hopkins?- LEAVE US A VOICEMAIL at 508-927-1267!- We're now an affiliate of Fangoria! Visit Fangoria's Shop & use code HOMETOWNHORRORPOD for an exclusive 20% discount!- A reminder that we're now a part of Horror Facts Magazine!- All Music, Sound Editing & Audio Production by Shaun O'Loughlin of Sky Wheel Media#Zodiac #DavidFincher #JakeGyllenhaal #MarkRuffalo #RobertDowneyJr #ZodiacKiller #HorrorMovies #CrimeThriller #2007Movies #2007Horror #2007inFilm #HometownHauntsandHops #HauntsandHopsHorrorCon #HalfwaytoHalloween #SalemsLot #TheExorcist #Halloween #TheIslandofDrMoreau #HorrorPodcast #HorrorFactsDotCom #Fangoria #AHHPod #AmericasHometownHorror #PlymouthMA

Es ist ein Blick in die Herzkammer der Luxus-Industrie, der Heartbeat der neuen Generation. Was genau bedeutet new Luxury? Was wollen die Consumer heute? Was ist ihnen wirklich wichtig? Und wie können Brands die Menschen überhaupt noch erreichen und begeistern? Die Antworten gibt Highsnobiety in einer weltweit einzigartigen Studie. Jetzt liegt der neue Luxury Report 2024 vor. Ich habe Founder und CEO David Fischer deshalb in seinem Headquarter in Berlin besucht. Er hat Highsnobiety 2005 gegründet. Erst Streetwear-Blog, mittlerweile ist es ein Fashion-Universe. Agentur, Consultancy, Social Media Plattform mit Popup-Stores, eigenen Design-Drops und Offices von Amsterdam, London, Mailand, New York bis Sidney. David ist jetzt zum zweiten Mal bei TOMorrow. Das Comeback des Highend-Orakels: Sein Blick auf die Branche, die wichtigsten Trends und neuen Rules – jetzt hier in TOMorrow. Wenn Du mitdiskutieren möchtest: Schreib mir in die Kommentare oder hier auf Social Media: http://lnk.to/TOMorrow-Podcast und abonniere den Channel. Jetzt aber: Viel Spaß in der neuen Luxury World! Viel Spaß mit dem King of Cool, David Fischer!

During the recent NRB, Mike had the privilege of sitting down with David Fischer, a dynamic filmmaker whose movie will be out during Memorial Day weekend. "Sight" is the title, and it is based on a heartwarming true story. David explains how the movie's production was hit with the many impacts brought to all industries during the pandemic. But he also sees how God used those challenges in an incredible way.

Our editor-at-large Fredrik Ekström sits down with the team behind Highsnobiety about their report The new outdoor.In this episode you will hear from: – David Fischer, Founder, Highsnobiety – Harry Bainbridge, Strategy Director, Highsnobiety We talk about:– The convergence lifestyle and outdoor– The role of cultural pioneers in this development– How Highsnobiety has collaborated with outdoor trade show ISPOHost: Konrad Olsson, Editor-in-chief and Founder, Scandinavian MIND. Hosted on Acast. See acast.com/privacy for more information.

Special Guest David Fischer Join me and David Fischer from landmarkgold.com on The Steve Noble Podcast. Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

Analyse von David Fischer, Principal bei HV Capital, und Julius Lühr, seit gestern Partner bei Acton Capital:Das Münchner Auto-Abo-Startup Finn hat in einer neuen Finanzierungsrunde 100 Millionen Euro von Investoren erhalten, darunter Planet First Partners und bestehende Investoren wie HV Capital, Korelya Capital, UVC Partners und Picus Capital. Diese Kapitalaufnahme soll vor allem für die Beschleunigung des Übergangs zur Elektrifizierung ihrer Flotte genutzt werden, mit dem Ziel, den Anteil an Elektroautos auf 80% bis Ende 2027 zu erhöhen.Das LegalTech Harvey.ai mit Sitz in San Francisco hat in einer Series-B-Finanzierungsrunde 80 Millionen US-Dollar eingesammelt und wird nun mit 715 Millionen US-Dollar bewertet. Diese Runde wurde von Elad Gil und Kleiner Perkins angeführt. Harvey plant, das frische Kapital für die Erweiterung seines Ingenieurteams und die beschleunigte Entwicklung seiner SaaS-Plattform zu verwenden. Weitere Links: Unsere einzigartige Plattform mit allen Informationen, Akteuren und Unternehmen der deutschen Startup-Szene Unser täglicher Startup-Newsletter mit über 25.000 begeisterten Abonnenten: Hier findest Du eine Übersicht.Fragen/Anmerkungen an die Redaktion? Sende eine E-Mail an redaktion@startup-insider.comAlle Infos zu ausgewählten Werbepartnern findest du hier.→ Lust auf mehr Podcast? Hier findest du unser Verzeichnis mit den top 100 internationalen Startups- und Tech-Podcasts

Im unendlichen Podcast spricht der Mode-Unternehmer über harte Gründungsjahre mit wenig Geld. Und darüber, wie sich sein Leben als Jude in Deutschland verändert hat.

Dr. David E. Fischer graduated from Stanford University with a BA degree in philosophy and went on to graduate studies at Fuller Theological Seminary and Princeton Seminary. Dr. Fischer founded Living Word Bible College in Southern California in 1971. He wrote curricula for 15 courses, including many chapter by chapter Bible book studies, and was a teacher for students from around the world for over 35 years. He has led worship symposiums in 20 different countries and authored a number of books, his latest being The Future Great Planet Earth: What they never told you about the last days, which you can download at Amazon, here.

Find us at facebook.com/tryingtolikeit

Full Money Monday! Steve talks to David Fischer for the whole show about Gold and how it is performing as well as where the dollar is going. Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

David Fischer is the associate head beach and indoor volleyball coach at UNCW. With his extensive experience building programs and an amazing skill to play the piano this is a must listen! --- Support this podcast: https://podcasters.spotify.com/pod/show/michael-hobson4/support

Full Money Monday! Steve talks to David Fischer from landmarkgold.com about our money crisis in the U.S. and where we are headed. Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

FULL Money Monday! Steve talks to David Fischer from Landmark Gold about the economy and where the American dollar is headed. Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

It is National Fentanyl Awareness Day - Steffan recaps a candlelight vigil near the Capitol last night and goes over numbers. We play an interview with Rachel Wels, mom of Aaron who was 37 years old and father of four. Then - a prayer from last night. We wrap the hour with the return of "Money Monday" with David Fischer, www.landmarkgold.com See omnystudio.com/listener for privacy information.

We've re-branded for today: The TubbX Show. New homeless numbers in Denver are terrible - up 32% this year. We've got a new cookie/sponsor for the summer. Then - we discuss the lawsuit filed by the DOJ against Texas today in relation to spinning concertina wire barriers in the Rio Grande. It's the 40th anniversary of George Brett's "Pine Tar Game." Music Monday with Jennifer Lopez, 54 today. We wrap the hour with Money Monday at David Fischer, www.landmarkgold.com See omnystudio.com/listener for privacy information.

Happy Monday! Let's go win the Mega Millions or Powerball! Denver in Decay has a new mayor. We play sound of the swearing-in, the poet laureate (eyeroll) and Mike Johnston from the ceremony. Will anything change in first 100 days or even in his first term? Calls and texts. Music Monday with Luke Bryan - turns 47 today and in Denver 7/29. Then - Steffan and Kyle Clark agree on that documentary on Michael Hancock. Hell has frozen over. We wrap the hour with Money Monday and David Fischer www.landmarkgold.com  See omnystudio.com/listener for privacy information.

Steffan just back from the Arapahoe County Justice Center - another court appearance for Robin Niceta. She's accused of false reporting against an Aurora Councilwoman and even faking her own brain tumor. Then - cocaine found at the White House Sunday night (where's Hunter!?) CBS sound and from The Bag of Rocks. The Philadelphia mass killer was allegedly a man dressed as a woman - killed five total strangers and shot two kids. Zero mention of the FACTS on NPR, et. al. Music Wednesday with "Van Hagar." Then - a recap of the 2023 Nathan's Hot Dog-eating contest. We wrap the hour with David Fischer, money news www.landmarkgold.com See omnystudio.com/listener for privacy information.

Cash Vs. Gold Steve talks to David Fischer from landmarkgold for the whole show about our failing economy and a new currency. Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

Happy Monday! A plea deal for the Club Q killer in Colorado Springs. Sneaky $40M deal the Denver City Council is about to enter into to care for "migrant guests." Sound from NYC Pride Parade: "... we're coming for your children." The latest on the Wagner uprising in Russia over the weekend and the latest on the Titan submersible last week. Then - oh, the poor Rockies. High(low)lights from Saturday's 25-1 loss to the Angels. Yikes. We wrap the hour with Money Monday, David Fischer, www.landmarkgold.com See omnystudio.com/listener for privacy information.

Biden Hot Water? Steve talks about Joe Biden and the developments of his son and money schemes. David Fischer calls in the last segment. Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

Steffan is back - on of the warmer days of the year to date! A Biden and Fetterman recap from PA. Hunter Biden reaches a ridiculous deal with the DOJ - nothing about that pesky laptop. RIP to former Rockies broadcaster George Frazier. Tune Tuesday with The Beach Boys - Brian Wilson's 81st birthday. Then - an update on the Titanic sub missing and running low on oxygen. Calls/texts. There's a (fairly) new homeless encampment near 225/Parker Rd. This is a CDOT issue. Why no action? We wrap the hour with Money Monday on a Tuesday with David Fischer, www.landmarkgold.com See omnystudio.com/listener for privacy information.

Rain and wild weather as we begin. Donald Trump is in South Florida for court tomorrow. Tweet watch over the weekend: Rep. Jenny Willford mad at Northglenn councilmembers for walking out of a Pride vote - yet she said nothing about The Colorado Six... and CU issued a "colored" tweet last week. Then - he's calling it his "Hood to the House" campaign... Tay Anderson is leaving the DPS Board of Education to run for a State House seat. We dig back into the archives for some ridiculous Tay Tay sound. Music Monday with Easton Corbin. We wrap the hour with Money Monday and David Fischer, www.landmarkgold.com  See omnystudio.com/listener for privacy information.

The January 6th breach of the U.S. Capitol resulted in one of the most extensive criminal investigations spearheaded by the FBI in the history of the United States. In today's episode, Serge and Clarke speak with attorney David Fischer, who represented the alleged mastermind of the breach: Thomas Caldwell. Caldwell's acquittal of the most serious charges shocked the D.C. press corps. This is a fascinating interview about the accused, the defense strategy, and the trial. 

Happy (mostly) rainy Monday! We welcome Denver Mayoral candidate Kelly Brough www.kellybrough.com joins us on the Election Day eve. Then - people are very, very stupid... as evidenced by what happened recently at Yellowstone National Park. Music Monday with covers - DJ Leroy's choices. We wrap the hour with Money Monday and David Fischer with www.landmarkgold.com See omnystudio.com/listener for privacy information.

Banks are Collapsing? Steve talks to David Fischer for the whole show about banks collapsing, where gold is going, and financial issues. Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

Welcome to Tuesday! Hope you had a memorable Memorial Day weekend. NBA Finals: Nuggets host the Miami Heat. The latest on the debt ceiling with sound from CBS News. Calls/texts. It's a Tune Tuesday with Poco. One week until the Denver Mayoral election - Steffan's thoughts on potential change. We wrap the hour with David Fischer - we discuss the debt ceiling agreement and where we are. More on Landmark Capital at www.landmarkgold.com See omnystudio.com/listener for privacy information.

We start with a family discussion on young doctors, air fryers and air quality (very, very bad in Denver!) Dr. Jim Craig is in court for a status conference this hour. Then - what state should Colorado model itself after when it comes to fentanyl distribution? The answer may surprise you. Sound and discussion. A mellow Music Monday with John Denver and James Taylor. The latest on debt ceiling talks, the alleged Idaho mass murderer and we wrap the hour with David Fischer and Money Monday - www.landmarkgold.com See omnystudio.com/listener for privacy information.

Steffan is back - and we're at war with Kyle Snark and Narcan 9News. First - an update on the CORA requests on The Colorado Six. You will not believe how many "hours" and how much money the state says will be needed to share the reps' email communication about that fallen peace officer resolution. As for the war: it's a hoot: Twitter and FB battles, name-calling. etc. We wrap the hour with Money Monday on a Tuesday with David Fischer, www.landmarkgold.com See omnystudio.com/listener for privacy information.

Happy Monday - another mass shooting, this one in Texas. A three-year-old and his parents, two little girls among the dead. More on the murderer. A nod to the 4th anniversary of the STEM school shooting and Elbert County Republicans. Then - more on the final day of the legislature today AND how they started this past Saturday's session with shame and guilt about The Colorado Six. We wrap the hour with David Fischer, www.landmarkgold.com See omnystudio.com/listener for privacy information.

Full Money Monday! Steve talks to David Fischer for the whole show today for Money Monday about gold and how banks are going bankrupt. Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

Happy Monday - we begin with the 27 CO Dems who voted against harsher penalties for adults who indecently expose themselves to minors. Calls and texts. Comrade/Aurora City Councilman Juan Marcano is again calling the GOP "a sadistic death cult." The Texas manhunt continues for the killer of five - he'd been deported five times prior. Music Monday with Aerosmith as it plans a 50th anniversary "Peace Out & Farewell" tour - Denver Nov 19. We wrap the hour with David Fischer and www.landmarkgold.com and the latest SpaceX launch.See omnystudio.com/listener for privacy information.

Catching Up with the CRAZY news Steve talks about crazy news. What is happening now? He talks to David Fischer in the last segment about our economy. Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

Full Money Monday with David Fischer Steve has a full money Monday show with David Fischer on Zoom to talk about gold and what will happen to the U.S. dollar. Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

Full Money Monday! Steve talks to David Fischer from Landmark gold for a Full Money Monday. They catch up on gold and the economy. Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

FULL Money Monday Steve talks to David Fischer for a full Money Monday in which they discuss gold and the U.S. dollar as well as digital currency. Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

Full Money Monday! Steve has David Fischer from Landmarkgold on zoom for the whole show. They talk about the economy and where it is. Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

Teens Discipling Teens? Steve talks to students and a teacher from Iron Academy to talk about the school. David Fischer calls in the last segment. Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

Full Money Monday! Steve talks to David Fischer for the whole show. They talk about jobs, currency, and inflation. How bad is it? Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You! 

Keith Getty, from Getty Music, highlights his important show at Carnegie Hall, inside the Stern Auditorium, on the Perelman Stage on Thursday, December 15th, at 7:30PM ET. You can get tickets now by going onto gettymusic.com/nyc22. Tom Tradup, a Vice President of News & Talk Programming at the Salem Radio Network looks at how the Left is using Tik Tok to be a Grinch this Holiday season and chastising the Church for not doing more over a Christmas carol and pageant. David Fischer from Landmark Gold & Capitol looks at Jerome Powell's latest commentary on the slowing rate hikes while adjusting for the latest job #'s and the price of inflation.